Crisugabalin

DB19300InvestigationalSmall molecule

Crisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin).

Mechanism: Pharmacologically active on Voltage-dependent calcium channel subunit alpha-2/delta-1 and Voltage-dependent calcium channel subunit alpha-2/delta-2
Curator reviewed
Formula / weight: C₁₂H₁₉NO₂ · 209.289 g/mol (avg)
Code names: HSK-16149

Resolves to

Compound

UNIIQ3MK7E8686CAS2209104-84-5

Structure

InChIKeyWCEFMBSFXJUREW-LIJGXYGRSA-NSMILES[H][C@@]12C[C@H]3C[C@]1([H])[C@](CN)(CC(O)=O)[C@]2([H])CC3

Targets

P54289CACNA2D1Q9NY47CACNA2D2

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

19Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Crisugabalin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account